Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054858 | 0.77 | KDM4E (0.40) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL6419496 | 0.77 | — | — | |
| SCHEMBL29540353 | 0.77 | — | — | |
| SCHEMBL9122150 | 0.77 | KDM4E (0.40) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1054855 | 0.77 | KDM4E (0.40) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL18174176 | 0.77 | RNPEP (0.40) | MAPT | |
| SCHEMBL30165075 | 0.77 | — | — | |
| SCHEMBL7648952 | 0.76 | KDM4E (0.39) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL28489157 | 0.76 | KDM4E (0.39) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL28479862 | 0.76 | KDM4E (0.39) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3967300-B1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF INFECTIONS AND/OR INFLAMMATIONS | ANVEST GROUP S R L (IT) | 2023-08-16 | — | — | EP | claimed |
| EP-3967300-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF INFECTIONS AND/OR INFLAMMATIONS | Laboratori Nutriphyt S.r.l. (IT) | 2022-03-16 | — | — | EP | claimed |
| US-20230392145-A1 | PROMOTING NUTRIENT ABSORPTION THROUGH THE COLON | CORNELL UNIVERSITY | 2023-12-07 | — | — | US | disclosed |
| EP-3967300-B1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF INFECTIONS AND/OR INFLAMMATIONS | ANVEST GROUP S R L (IT) | 2023-08-16 | — | — | EP | disclosed |
| EP-3967300-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF INFECTIONS AND/OR INFLAMMATIONS | Laboratori Nutriphyt S.r.l. (IT) | 2022-03-16 | — | — | EP | disclosed |
| EP-3967300-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF INFECTIONS AND/OR INFLAMMATIONS | Laboratori Nutriphyt S.r.l. (IT) | 2022-03-16 | — | — | EP | disclosed |
| US-20220008411-A1 | TOLL-LIKE RECEPTOR 7 OR 8 AGONIST-CHOLESTEROL COMPLEX AND METHOD OF PREPARING SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2022-01-13 | — | — | US | disclosed |
| EP-3889251-A1 | CULTURE MEDIA FOR MYCOPLASMA | Fundació Centre de Regulació Genòmica (ES) | 2021-10-06 | — | — | EP | disclosed |
| EP-3838260-A1 | IGG:TGF RII FUSION PROTEIN COMPOSITION | Ares Trading S.A. (CH) | 2021-06-23 | — | — | EP | disclosed |
| EP-2363122-B1 | Implant pellet comprising clonidine to treat pain locally | MEDTRONIC INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2248517-B1 | Concentrated mast cell stabilizing pharmaceutical formulations | PARI PHARMA GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| WO-2004006900-A2 | SULPHYDRYL COMPOUNDS IN COMBINATION WITH SULPHONE OR SULPHNAMIDE CONPOUNDS FOR USE IN MICROBIAL INFLAMMATORY DISEASES | IMMUNE NETWORK LTD. (CA) | 2004-01-22 | — | — | WO | disclosed |
| US-20020179103-A1 | Antioxidant enzyme compositions for use with cigarettes | HERSH THEODORE (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020117180-A1 | Glutathione, green tea, grape seed extract to neutralize tobacco free radicals | HERSH THEODORE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6415798-B1 | SMOKE FILTER | THIONE INTERNATIONAL, INC. | 2002-07-09 | — | — | US | disclosed |
| US-6228347-B1 | REDUCED GLUTATHIONE AND SELENIUM FOR GUM DISEASE | THIONE INTERNATIONAL, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6011067-A | THE COMBINATION OF L-GLUTATHIONE AND SELENIUM THAT ACTS AS ITS SYNERGISTIC CO-PARTNER, BOTH INCORPORATED IN A SUITABLE TOPICAL CARRIER. | THIONE INTERNATIONAL, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0792137-A4 | ANTIFUNGAL TREATMENT OF NAILS | JOHNSON & JOHNSON CONSUMER (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0792137-A1 | ANTIFUNGAL TREATMENT OF NAILS | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996019186-A1 | ANTIFUNGAL TREATMENT OF NAILS | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008411-A1 | TOLL-LIKE RECEPTOR 7 OR 8 AGONIST-CHOLESTEROL COMPLEX AND METHOD OF PREPARING SAME | TLR8, TLR7, TLR3 | KDM4E 3637/4885MAPT 4510/4885THRB 343/4885 |
| US-20230392145-A1 | PROMOTING NUTRIENT ABSORPTION THROUGH THE COLON | FABP2, SLC10A2, SLC19A1 | KDM4E 4496/4885MAPT 4844/4885THRB 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.